SCM
AVIR icon

Sterling Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Sterling Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.5K Sell
2,318
-1,779
-43% -$8.17K ﹤0.01% 2260
2025
Q4 		$14.6K Sell
4,097
-1,192
-23% -$3.79K ﹤0.01% 2403
2025
Q3 		$15.3K Buy
5,289
+3,109
+143% +$10.6K ﹤0.01% 2264
2025
Q2 		$7.85K Buy
2,180
+849
+64% +$2.53K ﹤0.01% 2277
2025
Q1 		$3.98K Sell
1,331
-1,141
-46% -$3.56K ﹤0.01% 2278
2024
Q4 		$8.28K Buy
2,472
+2,227
+909% +$7.4K ﹤0.01% 2248
2024
Q3 		$821 Buy
+245
New +$888 ﹤0.01% 2641

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Sterling Capital Management's AVIR Position: Q1 2026 in Review

Sterling Capital Management reduced its Atea Pharmaceuticals (AVIR) stake by 43% in Q1 2026, selling an estimated $8.17K and leaving 2,318 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2260.

Sterling Capital Management first reported a position in AVIR in Q3 2024 and has held it in 7 quarters since. The position peaked at $15.3K in Q3 2025. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Sterling Capital Management held 2,318 shares of Atea Pharmaceuticals worth $12.5K as of Q1 2026.
  • Sterling Capital Management sold 1,779 Atea Pharmaceuticals shares in Q1 2026, an estimated $8.17K.
  • Atea Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2260 holding.
  • Sterling Capital Management first reported a position in Atea Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Atea Pharmaceuticals position peaked at $15.3K in Q3 2025.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.